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1. Introduction
The public health ethics look at the moral basis of the health of human as a guiding support
put in place to maximize welfare, and therefore health as a component of welfare [1,2]. This
view frames the core moral challenge of public health as balancing individual liberties with
the advancement of good health outcomes.
An alternative view of public health ethics characterizes the fundamental problematic of public
health ethics differently: what lies at the moral foundation of public health is social justice [2].
While balancing individuals' liberties with promoting social goods is one area of concern, it is
embedded within a broader commitment to secure a sufficient level of health for all and to
narrow unjust inequalities [2, 3]. Another important area of concern is the balancing of this
commitment with the injunction to maximize good aggregate or collective health outcomes.
Public health ethics has therefore a strong moral connection to broader questions of social
justice, poverty, and systematic disadvantage [3,4].
1.1. Historical ethical perspective
Although there have been some manifested concerns about the vulnerability of human subjects
implicated in clinical research for over a century, it was the scandals and tragedies of the Nazi
doctors during the second World War that gave birth to the discipline of bioethics [4, 5]. Other
recent concerns in bioethics are attempting to extend ethical debate beyond the one-to-one
physician-patient relationship, to enter the domain of public health where focused is geared
towards the health of the entire populations. In the Africa setting, these extended concerns are
being driven in part by the persisting iniquities and disparities in the health status of the low
income resource countries and the rich countries, the differences in access to health services,
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the differences in the effort put into solving health problems, whereby the larger health
burdens of the South receive scarce research attention, and the fewer problems of the North
receive most of the attention in what has been termed the 10/90 gap [6, 35]. More attempts
made to redress these inequalities have led to greater research investment and North-South
research collaboration with the aim of solving the major health problems affecting the
population in the poor countries of the South [7, 35].
1.2. The Ethical fundamental principles
Four fundamental principles of ethics have been universally recognized namely; autonomy,
beneficence, non-maleficence and justice. These principles universally deals with the respect
for all other humans as moral equals, making sure that all our actions are intended to achieve
results with less harm, and treating others with fairness and equity [8, 48].
1.2.1. Beneficence and non maleficence
The principle of beneficence and non-maleficence are best considered together as they are like
mirror images of each other. Literally beneficence means doing good and non-maleficence
means avoiding evil or harm [9, 38, 42].
1.2.2. The harm principle
It is likely that no classic philosophical work is cited more often in the public health ethics
literature than John Stuart Mill's essay “On Liberty” [10]. In that essay, Mill defends what has
come to be called the harm principle, in which the only justification for interfering with the
liberty of an individual, against her will, is to prevent harm to others. The harm principle is
relied upon to justify various infectious disease control interventions including quarantine,
isolation, and compulsory treatment. In liberal democracies, the harm principle is often viewed
as the most compelling justification for public health policies that interfere with individual
liberty [10, 19]. For example, a prominent view in the United States is that it was not until the
public became persuaded of the harmful effects of “second hand smoke” that the first signif‐
icant intrusion into smoking practices—the banning of smoking in public places—became
politically possible. Perhaps because of the principle's broad persuasiveness, it is not uncom‐
mon to see appeals made about harm to others in less than obvious contexts [11]. Defenders
of compulsory motorcycle helmet laws, for example, argued that the serious head injuries
sustained by unprotected cyclists diverted emergency room personnel and resources, thus
harming other patients[12, 32]. The harm principle has been interpreted to include credible
threat of significant economic harm to others as well as physical harm. Regarding smoking
policy, various restrictions on the behavior of smokers have been justified by appeal to the
financial burden on the health care system of caring for smoking-related illnesses [13].
As with all such principles, questions remain about its specification. How significant must the
threat of harm be, with regard to both its likelihood and magnitude of effect? Are physical
harms to the health of others to be weighted more than economic harms or other setbacks to
interests? Whether interpreted narrowly or broadly, there are limits to the public health cases
that can plausibly be placed in the harm principle box [14, 15]. Moreover, in the context of
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commitments to social justice and general welfare, and the other justifications described above,
too exclusive a focus on the harm principle can undermine otherwise justifiable government
mandates and regulation. It is undeniable that individuals have much broader and more multi-
dimensional interests than narrowly self-directed physical ones, and in that sense, it is not
unreasonable to have a fairly expansive understanding of “harm” in a public health context
[16-18]. The summary of the fundamental ethical principles and their applications in public
health and biomedical research illustrated by Chilengi [17], is shown in table 1.
PRINCIPLES DESCRIPTION APPLICATION
AUTONOMY Human beings are born as
autonomous agents. This autonomy
gives them the rights to self
determination that must be respected.
Autonomy demands that the wishes of
all persons must be respected and we
do so by asking their opinion or
willingness to get involved or not
Informed Consent
NON-MALEFICENCE Primun non nocere, Latin translation
for first, do no harm. Research must
primarily and actively seek not to do
harm regardless of the extent of
potential good that may arise from the
research.
Evaluate foreseeable risks and
minimize harm
BENEFICENCE While minimizing harm research must
be of benefit to individuals and society
at large. Beneficence is a group of
norms for providing benefits and
balancing benefits against risks and
costs
Maximize benefits
JUSTICE A group of norms for distributing
benefits risks and costs fairly. The
benefits of research must equitably be
shared by those who bore the cost and
risk of the research.
Fair subject selection and fair
distribution of benefits.
Table 1. Summary of fundamental ethical principles and their applications in public health and biomedical research [17].
2. Some challenges related to public health research ethics
There is no standardized method of organizing either the ethics of clinical practice, or the public
health and biomedical research. Although these distinctive concerns are often dealt with under
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the broader term of bioethics, sometimes bioethics is presented as the equivalent of medical
ethics. Whichever approach is preferred, a key question remains: what distinguishes public
health ethics from medical ethics? The answer lies in the distinctive nature of public health
[23,51].
Public health has four characteristics that provide much of the subject matter for public health
ethics as follows: (1) its promotion involves a particular focus on prevention; (2) it is a public
or collective good; (3) it involves an intrinsic outcome-orientation and (4) its promotion often
entails government action; [11, 24-26].
First, in public health the main point of concern is the population, not individuals. Public health
is, by its very nature, a public, communal good, where the benefits to one person cannot readily
be individuated from those to another, though its burdens and benefits often appear to fall
unevenly on different sub-groups of the population [25]. This raises a particular set of
challenges the public health ethics has to address. Whose health are we concerned about, and
then what sacrifices is it acceptable to ask of individuals in order to achieve it? Is there a
difference between public health and population health? And why is public health a good
worth promoting? [26]. Any answer to these questions has to take into account the fact that
public health measures are often based on the prospect of benefit to individuals, not immedi‐
ately securable benefits [23, 27].
Second, promoting public health involves a high degree of commitment to the prevention of
disease and injury. However, although much of the discussion surrounding public health
focuses primarily on this preventive aspect, public health agencies and services also involve
diagnosing and treating illnesses, with all the attendant clinical services that those activities
require [28, 29].
Achieving good public health results frequently requires government action: many public
health measures are coercive or are otherwise backed by the force of law. Public health is
focused on regulation and public policy, and relies less often on individual actions and
services. In this as in all other areas of official state action, we therefore have to address tensions
among justice, security, and the scope of legal restrictions and regulations [19, 30].
2.1. The rationale of public health programs and policies
Public health draws its fundamental legitimacy from the essential and direct role that health
plays in human flourishing, whether that role is understood ultimately in terms of maximizing
health or promoting health in the context of advancing social justice [31, 38]. This general
justification is sometimes too broad, however, to provide sufficient moral warrant for specific
public health policies and institutions, especially when, as is so often the case, these policies
and institutions are implemented by the state and affect the liberty or privacy of corporate or
individual persons (Beauchamp, 2010). This section puts forward six justifications or reasons
that can be put forward to defend a particular public health institution or policy [32].
Two observations are worth making at the outset. First, public health policies are rarely
defended by only one reason. Usually a mixed set of justifications can be provided. For
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example, tax policies intended to decrease cigarette consumption can be defended both by
appeal to paternalism and by appeal to reducing the harms of second hand smoke to children
in the home and in automobiles[20, 33]. Second, the impact of public health policies is often
not uniform across all the individuals affected by the policy, and thus different justifications
are sometimes put forward specific to these different people. This complexity is unavoidable,
since it results from the nature of public health: The focus of public health is population health,
but populations are rarely internally uniform with regard to all features that are morally
relevant to any particular policy [28, 34-35]. Some people may stand to benefit from the policy
while others may not. Moreover, in line with concerns about democratic legitimacy and state
over-reaching, some members of the population may support the aims of the policy while
others may object [36].
The first four of the justifications for public health policies- overall benefit, collective efficiency/
action, and fairness- speak specifically to the context in which some members of the affected
population are not directly benefited by the policy or object to it [37]. The next two justifications
appeal to the significance of harm, both to others and to oneself. They apply more specifically
to traditional concerns about balancing respect for liberty with advancing health and are more
prevalent in the public health ethics literature than the previous four. In the fifth justification,
the argument is from a relatively uncontroversial Millian harm principle, and in the sixth
justification, from somewhat more tendentious paternalistic principles [12, 38].
2.2. Some benefits of public health
It is difficult to estimate direct benefits of the majority of public health interventions since some
of these interventions target many health problems and many interventions can contribute to
reduce the burden of one health problem. Furtherer, it is known that some of health determi‐
nants like those associated to environment change naturally. At individual level, it is even
more complicated as the efficacy of public health intervention is the absence of a particular
health event that is difficult to justify by the intervention [39, 40].
Generally, we all benefit from having public health interventions, and from having trusted
regulatory agencies such as the Centers for Disease Control and Prevention (CDC) or the Food
and Drug Administration (FDA) make decisions about such interventions and their reach [16,
41]. All things considered, having public health regulation is better than not having it. Having
public health decisions made on the basis of overall statistics and demographic trends is
ultimately better for each one of us, even if particular interventions may not directly benefit
some of us. Thus, the task of public health ethics is not necessarily to justify each particular
intervention directly [16, 41]. Rather, public health interventions in general, as long as they
stay within certain pre-established parameters, can be justified in the same way a market
economy, the institution of private property, or other similarly broad and useful conventions
that involve some coercive action but also enable individuals to access greater benefits can be
justified: when properly regulated and managed, its existence is by and large better than its
absence for everyone [43].
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2.3. The public health policy action strategies
A related justification views health as a public good the pursuit of which is not possible without
ground rules for coordinated action and near-universal participation. The public health is
viewed as having the structure of a coordination or collective efficiency problem. For example,
if one person (or a sufficient critical mass of such persons) decides not to abide by a public
health regulation because the regulation does not directly benefit he or she otherwise objects,
the ramifications will likely be felt by others in her environment and beyond (Daniels, 2008).
Everybody has to participate because, failing their involvement, neither they nor anyone else
can reap the benefit of a healthy society (Crawford, 2008).
The collective efficiency class of arguments relies on claims about the sheer number and
technical complexity of the decisions that need to be made to protect health in the environment
and in the market place, as well as the indivisible character of responses to some health threats
[15, 21, 46].
2.4. Public health community engagement
The communitarian argument relies on the idea that is good for the whole is necessarily good
for its parts [47]. Communitarians view individuals' identities and the meaningfulness of their
lives as indelibly tied to the well-being of their community. Clinical research in a developing
nation to be deemed ethical requires community engagement, so that the research can
contribute to the social value. Thus, on this view, public health interventions are good for
individuals simply because they benefit the community as a whole. It thus encourages a
cooperative way of thinking about public health interventions. Its main shortcoming, however,
is that it assumes too tight a connection between individuals and the communities to which
they belong, thereby incurring the potential for abuses of less privileged individuals within
certain communities in the name of communal well-being [48]. It is unfortunately not always
the case that the interests of individuals and the interests of their communities coincide in this
convenient way. Rather, such interests often come apart, and can come into conflict in ways
that require us to address yet again the questions: how much can we ask of individuals for the
sake of others, of which individuals can we ask sacrifices for the sake of the community, and
why? There is a conceptual distance between what is good for particular individuals, what is
good for all individual members of a community, and what is good for the community [8, 49].
Thus, there can sometimes be direct trade-offs between what is good for the community and
what is good for particular individuals within it. Notwithstanding these difficulties, this is
certainly a strategy worth giving serious consideration as a possible avenue for the justification
of public health interventions, particularly in some contexts where there is a strong sense of
community solidarity [3, 50].
3. Aspect of justice and fairness in public health
Whether social justice is viewed as a side constraint on the beneficence-based foundation of
public health, or as foundational in its own right, there is broad agreement that a commitment
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to improving the health of those who are systematically disadvantaged is as constitutive of
public health as is the commitment to promote health generally (Powers and Faden 2006,
Institute of Medicine's Committee for the Study of the Future of Public Health [50-52].
In this regard, there is an intimate connection between public health and the field of health
and human rights. Many in public health accept that there is a fundamental right to health, as
codified in the United Nations Universal Declaration of Human Rights or otherwise, although
there is less agreement about the justification for such a right or what precisely the right entails
[24]. A key question for public health ethics is on whom the duties generated by a right to
health fall. Since so many of these duties require collective action. The governments are obvious
candidates, but so, too, are other social institutions in the private sector as well as those global
in structure that bear on the right to health [8, 35]. A failure on the part of these institutions to
ensure the social conditions necessary to achieve a sufficient level of health is an injustice that
on the view of many violates a basic human right. Note that as a basic human right, the claims
of the right to health are not in any fundamental respect restricted to national borders but
rather fall on the human community [9].
When inequalities in health exist between socially dominant and socially disadvantaged
groups, they are all the more important because they occur in conjunction with other disparities
in well-being and compound them [1, 15]. Reducing such inequalities are specific priorities in
the public health goals of national and international institutions.
One of the most difficult challenges for public health ethics emerges when moral function
conflicts with the injunction to improve, if not maximize, aggregate or collective health
outcomes [39]. Although the health of the world's most desperately poor can in many cases be
improved by extremely cost-efficient interventions like basic childhood immunizations and
vitamin supplementation, reducing other unjust inequalities in health can consume significant
resources.
Another challenge in social justice for public health ethics emerges when the health needs of
systematically disadvantaged groups conflict with other dimensions of well-being as well as
with considerations of collective efficiency. Targeting a public health program to poor and
minority communities can sometimes both serve social justice concerns and be efficient if, for
example, the health problem the intervention targets occurs disproportionately in these groups
[7, 42]. At the same time, however, if the health problem is itself associated with stigma or
shame, targeting the poor and minorities may reinforce existing invidious stereotypes, thereby
undermining another critical concern of social justice, equality of social respect. In such cases,
public health authorities must decide whether a commitment to social justice requires
foregoing an efficient, targeted program in favor of a relatively inefficient, universal program
that also may produce less improvement in health for the disadvantaged group (thus failing
to narrow unjust inequalities) in order to avoid exacerbating existing disrespectful social
attitudes [19].
Some formal methods, including most notably cost-utility analysis, rely on what are referred
to as summary health measures in which mortality and diverse morbidities are combined in
a single metric such as a quality-adjusted or disability-adjusted life year. These measures, and
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the formal methods that employ them, sometimes rely on assessments of what may be only
vague individual preferences for trade-offs between different states of health or different kinds
of benefits. Moreover, they make morally problematic assumptions including, for example,
whether to differentially value years saved in different stages of life and about how to disvalue
specific disabilities [34]. Depending on how these and other assumptions are determined and
specified, summary health measures have been criticized as being ageist or not ageist enough,
as discriminating unfairly against people with disabilities, as failing to capture the moral
uniqueness of life-saving, as treating as commensurable qualitatively different losses and
benefits, and as failing to take adequate account of the claims of those who are most disad‐
vantaged [14, 50].
3.1. Burden distributions in ethical research
Another appeal that can be used to defend certain public health interventions that impose
unequal burdens on different members of a population relies on considerations of fairness.
The basic premise of this line or argument would be that burdens have to be roughly equivalent
for everyone [23]. The same could be said for certain public health “burdens,” understood as
both the burdens of disease and disability and the burdens of public health interventions.
Based on considerations such as a particular group's likelihood to contract a certain disease,
and their overall health status, other parts of the population can legitimately be asked to
“contribute,” as it were, in order to make the distribution of disease burdens more equitable
[9, 50]. For example, part of the rationale for requiring child immunization prior to enrollment
in school is that this is a way to ensure that low-income children, who are generally less healthy
than other children, have access to the needed vaccines [44]. Another example of public health
interventions that appear to be guided by this justification is rubella vaccination of children
for the sake of pregnant women and their fetuses [50]. This reasoning can help explain why
individuals are sometimes asked to bear public health burdens that do not directly benefit
them. However, the question of how far we can go in redistributing health-related burdens
will likely continue to plague any proponent of this justificatory strategy. Moreover, questions
about the plausibility of viewing health-related burdens as subject to distribution in this
manner may also arise [6, 17].
3.2. Paternalism
Paternalism is classically understood as interfering with the liberty of action of a person,
against his/her will, to protect or promote his/her welfare is as controversial as the harm
principle is uncontroversial (Dworkin 2005). Few public health interventions are justified
exclusively or even primarily on unmediated, classic paternalistic grounds, although many
more public health programs may have paternalistic effects. By contrast, other classes of
arguments that are sometimes described as paternalistic, including soft paternalism, weak
paternalism, and libertarian paternalism, are evoked more frequently [19, 21].
Soft and weak paternalism are usually interpreted as interchangeable, though they have
sometimes been taken to denote different concepts [14, 46]. A common interpretation defines
this kind of paternalism as interferences with choices that are compromised with regard to
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voluntariness or autonomy. Though a person might voice or hold a preference different from
the one that is sought for him, his preference is not entitled to robust respect if it is formed
under conditions that significantly compromise its autonomy or voluntariness, such as
cognitive disability or immaturity and, in very limited cases, ignorance or false beliefs [20].
Adaptive preferences are also considered compromised with regards to autonomy: sometimes,
individuals modify their preferences in order to be able to adapt to difficult, unjust, or
undesirable circumstances [32]. Such preferences also do not have the same standing as
preferences formed under normal conditions and are therefore viewed as subject to interfer‐
ence [32].
Libertarian paternalism defends interventions by planners (such as public health authorities)
in the environmental architecture in which individuals decide and act in order to make it easier
for people to behave in ways that are in their best interests (including their health), provided
two conditions are satisfied [5, 31]. First, individuals are steered by these interventions in ways
that make them better off, as judged by themselves. Thus, in libertarian paternalism there is
no attempt to contravene the will of individuals, in contrast to what some hold to be a necessary
feature of paternalism. Second, the interventions must not overly burden individuals who
want to exercise their freedom in ways that run counter to welfare. In this sense, libertarian
paternalism claims to be liberty-preserving, hence libertarian.
A key conceptual question about paternalism is whether the interference with individual
liberty must be against the person's will [3]. If this feature is a necessary condition of pater‐
nalism, then libertarian paternalism is inappropriately titled. From the standpoint of public
health ethics, however, whether libertarian paternalism is appropriately titled is less important
than the moral issues it raises and how it is justified [1, 52].
3.3. Mutual benefit
Finally, there is a more pragmatic reason to attend to public health in the developing world.
Beyond claims of justice, morality, and common decency, we live in a world where mobility
and interaction within and across countries is very high. Diseases such as SARS, H1N1, and
drug-resistant TB, as well as less headline-grabbing ailments such as cholera and malaria, are
not neatly contained within one national boundary. Citizens of all countries would benefit
from improving public health in the developing world. Contributing to the availability and
improvement of medical, sanitary, and other health-related resources for those who live in
poverty and deprivation is ultimately good for us all, whether we are in the habit of traveling
around the world or not [7]. There is also the need for understanding the emerging diseases
and those poverty related diseases that is of major economic concerns [36, 52].
4. Research for low income ecomomies
Medical research is sometimes undertaken in the low income economies in order to further
the understanding and treatment of diseases, not primarily for the benefit of those in the
developing world, but rather for the benefit of citizens of the developed world. In such cases,
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participants and their communities might well claim that they are entitled to share in the
benefits of the research [9, 16]. However, compensation to participants and their communities
is often non-existent or not nearly in line with the potential benefits their participation will
bring to those fortunate enough to have been born in a different geographical location [6, 36].
Note that this is a different issue from the question of whether researchers working on
indigenous diseases in the developing world have a duty to provide medical care or other
ancillary services to their research subjects [5, 21].This is less a question of justice as of research
ethics more generally.
4.1. Uneven research focus
Much medical research is focused on diseases that affect less than 10% of the world's popula‐
tion, while millions die every year from diseases that potentially could be prevented or more
easily treated if only enough research and other medical resources were devoted to them [1,
20]. Given the sheer numbers of people who needlessly die every day from such neglected but
widespread diseases, and given that the developed world clearly has the resources to change
that state of affairs, justice claims arguably also arise in this context [22, 35].
4.2. The legal compensatory claims
Many poor, underdeveloped countries that are massively underserved when it comes to public
health resources continue to suffer from the direct and indirect effects of historical, unjust
harms perpetrated by many of the world's wealthiest countries such as colonialism, war,
occupation, and other forms of violent economic exploitation [36, 43]. In many cases, harms
are more recent or are continuing, for example the diamond wars in Sierra Leone and other
African countries as well as the more general on-going exploitation of local natural resources.
Both the historical effects and the persistent effects of such violence and exploitation on public
health in those countries ground additional justice-based claims against the wealthy nations
to reduce the profound inequalities in health that exist between the world's poor and advan‐
taged people [8, 26].
4.2.1. The role of the ethics committee
There are many synonymous for committees that review and approve biomedical research
protocols to safeguard the dignity, rights, safety and well being of actual or potential research
participants (WHO, 2000; Tedlock, 1983).Terminologies such as Independent Ethics Commit‐
tee (IEC), Institutional Review Boards (IRB), Institutional Ethics Committee (IEC), National
Ethics Committee (NEC) and Ethics Review Boards (ERB) are interchangeably used. The two
WHO guidelines have addressed in details the description of what ERB are, or are intended
to be, recommended compositions, what ethical review entails, how they should operate, reach
decisions and communicate those decisions. Other publications have provided ethical
framework for evaluating whether proposed research is ethical (CIOMS, 2008, Emmanuel et
al., 2000; Amdur and Elizabeth, 2002. It is important therefore to look at the different roles of
stakeholders in ethical research.
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Responsibilities of the participants
The greatest role of ERB is to ensure that research that is conducted among the communities
is ethical. Also important to this obligation is to ensure that in its basic setup, composition,
operations and follow up activities are such that the mandate of protecting research partici‐
pants is carried out effectively.
Research and legal liability
Legal liability claims against health professionals were traditionally confined to those who
engaged in clinical practice. However, in recent years an increasing number of civil claims
have emerged in the health research realm. In this regard, three trends have emerged: (1) the
types of legal claims have diversified; (2) the number and types of defendants named in such
lawsuits have increased beyond researchers; and (3) class action lawsuits are increasingly
being lodged on behalf of groups of research subjects (Mello et al., 2003). While the over‐
whelming number of research-related lawsuits has arisen in affluent countries, the filing of
multi-jurisdictional lawsuits against drug maker, Pfizer, in relation to its Trovan drug trial in
Nigeria illustrates that developing countries are also becoming battlegrounds from lawsuits
against those involved in research. This work outlines the liability risks of researchers, host
institutions, research ethics committees, consulting bioethicists, and research sponsors
through a review of sample cases involving these parties.
There exist a number of liabilities in the ethical conduct of research involving all the stake‐
holder that can be outline as follows:
Research liability
This involves civil claims against researchers which in the early days centered around the
notion of informed consent If we consider the case of Wess versus Solomon (1989), the heirs
of a subject who died while a volunteer in a non therapeutic study successfully sued the
investigator and his university-affiliated hospital. The judge found the principal investigator
and hospital, through its research ethics committee responsible for not disclosing a rare fatal
complication caused by fluorescent dye and not adequately screening the subject who suffered
from undisclosed hypertropic cardiomyopathy.
Research ethics committee liability
Research ethics committee (RECs) or Institutional Review Boards (IRBs), are responsible for
assessing human research protocols for conformity to ethical principles (Zlotnik Shaul, 2002).
RECs liability has been recognized as far back as in the 70s, when the US National Commission
for the protection of Human Subjects of Biomedical and Behavioral research published a report
captioned Report and Recommendation: Institutional Review Board (NCPHSBBR, 1978).The
principles state that one who undertakes to protect others must act responsibly. IRB members
could be liable if they did not exercise reasonable care in carrying out their review. This may
occur if their approval led to a research activity and injuries that would not have occurred if
a reasonable person, confronted with the same information would have placed conditions on
the research that would have prevented the injury. Therefore an injured can possibly press
charges for negligence by the IRB members in assessing the risks and benefits of proposed
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research, or in approving consent procedures not necessarily likely to assure legally effective
consent.
4.2.2. Institutional liability
Institutional liability arises from the Common Law doctrine of vicarious liability, which holds
superiors accountable for the wrongs of their subordinates (Amir, 2009). Amir JA. Research
and Legal Liability. Acta Tropica, 2009;112S:S71-S75).An illustrated case is that in the US of
Berman versus Fred Hutshinson cancer centre (2002) where the husband of a research
participant (Hamilton) died in a chemotherapy trail brought filed a law suit against the Fred
Hutchinson Cancer Centre alleging that his wife’s consent to participate in the study was not
informed because the institution failed to disclosed the following:
That the researchers had no idea whether the relevant drugs would have any protective effect
against organ damage; Hamilton would not receive the planned dosage of the drug if she were
unable to ingest the oral version of the drug; seven prior protocol participants had died, one
of whom had suffered serious organ damage; and there were alternative treatments that were
less risky and were reporting a significantly higher cure rate. In summary Berman argued that
his diseased wife did not give informed consent to participate in the trial as she was not
informed that an experimental drug to prevent lethal side effects of chemotherapy was not
available was not available in the intravenous form. After trying to swallow the pills, the
participant vomited the pills and died. The trial court handling the case ruled that the Fred
Hutchinson Cancer Research Centre’s failure to disclose the unavailability of the intravenous
form of the drug invalidated Hamilton’s consent to participate in the trial.
Bioethicist liability
The bioethicist liability case can be exemplified in the Robertson case where the plaintiffs’
alleged that the consulting bioethicist in the matter was careless, negligent and reckless for the
following: failing to exercise reasonable care under all of the circumstance, in accordance with
the accepted bioethical practice; failing to follow and abide by by the guidelines set forth by
various governmental agencies and acting negligently.
Sponsor laibility
The most high profile lawsuit filed against a study sponsor are those lodged against the US
pharmaceutical firm, Pfizer, y the Nigerian plaintiffs and authorities. The lawsuits arose from
a 1996 drug study conducted by Pfizer in the Northern State of Kano during a meningitis
epidemic. In the US case of Abdullahi versus Pfizer Inc (2003), the plaintiffs, parents of the
child participants in the trial, alleged the use of the drug TROVAN on children with meningitis
was done without the parental informed consent and resulted in nearly a dozen dying, and
others being left with brain damage, paralysis and slurred speech. In January 2009, the US
Court of Appeals for the Second Circuit in New York overturned a lower court’s finding that
the cases brought by the plaintiffs could not be heard in the United States (Perlroth, 2009). In
April 2009, Pfizer reportedly settled the case for $75 million (Howden, 2009).However, the
settlement of the US case did not affect other pending cases against Pfizer in Nigeria such as
the $7 billion case lodged by the Nigeria Federal Government in June 2007 and a $2 billion case
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lodged by the Kano State Government (Sturcke, 2007).The Pfizer case is significant for various
reasons. To begin with, it illustrates that research participants in the developing countries are
gaining increasing awareness of their rights and are prepared to act accordingly. The second
point is that research conducted by US sponsors of research in developing countries is
actionable against those sponsors in the US. Thirdly, research liability lawsuits may also be
brought by government authorities, even though they were not the affected parties. Lastly,
liability suits may be filed concurrently in different countries and a judgment or settlement in
one country does not affect pending cases elsewhere. Some countries require sponsors and
investigators to obtain insurance coverage for trial participants for trial-related injuries as a
prerequisite to trial commencement. The Pfizer case demonstrates that it is important for
sponsors and investigators to have insurance cover clinical drug testing trials.
There exist other potential areas of law suit given the increase in multi-country, multi-national
collaborations. Potential lawsuits are emerging from legal issue with material transfer
agreement, data sharing agreement and intellectual property rights. The use and storage of
biological materials/samples, particularly those exported for storage and analysis to institu‐
tions in sponsor countries for use such as to determine biomarkers that confer protective
immunity where capacity to conduct such analysis is not available in host countries in the
developing countries. Solutions to solving such potential problems involve signing contractual
agreements, memoranda of understanding such as data sharing agreement (DSA), Material
Transfer Agreement (MTA), entered into between the disputing parties. Such agreements
should be negotiated between all relevant stakeholders before any clinical research can
commence, and that a dispute resolution mechanism are jurisdictional issues are prospectively
determined in the case of any foreseeable dispute.
4.3. Contribution of International Research Integrity (IRI) in public health research
promotion
National Science Foundation NSF implementation of Section 7009 of the America Creating
Opportunities to Meaningfully Promote Excellence in Technology, Education, and Science
(COMPETES) Act requires that the Authorized Organizational Representative complete a
certification at the time of proposal submission that the institution has a plan to provide
appropriate training and oversight in the responsible and ethical conduct of research to
undergraduates, graduate students, and postdoctoral researchers who will be supported by
NSF to conduct research. Additional information on NSF’s responsible conduct of research
(RCR) policy is available in the Award and Administration Guide, Chapter IV.B [46]. While
training plans are not required to be included in proposals submitted to NSF, institutions are
advised that they are subject to review upon request.
With the increasing globalization of science and engineering research and education, and the
associated issues related to the responsible conduct of research within a global context, NSF
recognizes that projects involving international partners may present special risks and
challenges. Maintaining high standards of ethical and scientific integrity helps to maintain
public trust in the research enterprise. An increasing number of authors have pointed to the
importance of mentoring and education in relation to the responsible conduct of science in
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preventing transgressions of scientific integrity. Just like in clinical research and biomedicine,
epidemiologists and other public health researchers have the responsibility to exhibit and
foster the very highest standards of scientific integrity [46]
The following resources are provided to assist in developing training and oversight plans for
the responsible and ethical conduct of research in an international context and to understand
the codes of conduct in other countries. NSF does not provide content or endorse these sites’
content, but provides them as possible resources.
4.4. National institute of health in public health research clinical excellence
The National Institute for Health and Clinical Excellence (NICE) is a special health authority
of the English National Health Service (NHS), serving both English NHS and the Welsh NHS.
It was set up as the National Institute for Clinical Excellence in 1999, and on 1 April 2005 joined
with the Health Development Agency to become the new National Institute for Health and
Clinical Excellence (still abbreviated as NICE). NICE carries out assessments of the most
appropriate treatment regimes for different diseases. This must take into account both desired
medical outcomes (i.e. the best possible result for the patient) and also economic arguments
regarding differing treatments. NICE have set up several National Collaborating Centres
bringing together expertise from the royal medical colleges, professional bodies and patient/
carer organizations which draw up the guidelines [47]. The centres are the National Collabo‐
rating Centre for Cancer, the National Clinical Guidelines Centre for Acute and Chronic
Conditions, the National Collaborating Centre for Women and Children´s Health, and the
National Collaborating Centre for Mental Health. The National Collaborating Centre then
appoints a Guideline Development Group whose job it is to work on the development of the
clinical guideline. This group consists of medical professionals, representatives of patient and
carer groups and technical experts. They work together to assess the evidence for the guideline
topic (e.g. clinical trials of competing products) before preparing a draft guideline. There are
then two consultation periods in which stakeholder organizations are able to comment on the
draft guideline. After the second consultation period, an independent Guideline Review Panel
reviews the guideline and stakeholder comments and ensures that these comments have been
taken into account. The Guideline Development Group then finalizes the recommendations
and the National Collaboration Centre produces the final guideline. This is submitted to NICE
who then formally approve the guideline and issues this guidance to the NHS [47].
4.5. Institute of tropical medicine and hygiene in public health research ethics
The London School of Hygiene and Tropical Medicine is an institution promoting research in
public health through the introduction of research training courses which aim at equipping
students with skills needed to appreciate and analyze public health problems in developing
countries, and to design and evaluate actions to improve public health. The course considers
issues of global health, development and the provision of health services from a multidisci‐
plinary perspective. All the public health students are expected to have a substantial experience
of planning or implementation of public health programmes, of teaching or research, in
developing countries. Graduates from this course work in global health, health service
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management, in health programmes in developing countries, in international and national
NGOs, and in research. In addition to MSc Public Health in Developing Countries. By the end
of the course students should be able to: demonstrate knowledge and understanding of theory
and practice in the core public health disciplines (epidemiology, statistics, social sciences,
health policy and health economics; demonstrate specialized knowledge and skills in other
areas relevant to public health from a wide range of options (e.g., primary health care, medical
anthropology, epidemiology and control of malaria, and population studies); apply these skills
to identify and assess public health problems in developing countries and evaluate actions
designed to improve public health; formulate public health strategies and approaches to public
health problems appropriate to a given culture and environment; and apply appropriate
research skills for evaluation and use of research findings.
4.6. World Health Organization (WHO) in public health research ethics
Health ethics has been an integral part of the activities of many units and departments at WHO
for many years and is addressed not only within the Department of Ethics and Social Deter‐
minants (ESD) and throughout the organization. ESD works collaboratively with staff from all
departments and the regional offices to identify, design, and carry out projects addressing the
ethics of health care, public health, and biomedical science. This encompasses projects that
originate in the department and those on which it provides advice and assistance to activities
located in other clusters and in regional offices. In October 2002, the World Health Organiza‐
tion launched its Ethics and Health Initiative to provide a focal point for the examination of
the ethical issues raised by activities throughout the organization, including the regional and
country offices, and to develop activities regarding a wide range of global bioethics topics,
from organ and tissue transplantation to developments in genomics, and from research with
human beings to fair access to health services.
Work in ethics and health is now carried out by the Department of Ethics and Social Determi‐
nants in the Innovation, Information, Research and Evidence cluster at headquarters. This
department is involved in a wide range of ethics activities, both on its own initiative and in
response to the needs of other parts of WHO. The specific projects, many of which link different
departments and involve experts from outside the organization, evolve in response to changes
in the field.
4.7. NEPAD in promoting public health research in Africa
The New Partnership for Africa’s Development (NEPAD) is a socio-economic development
programme of the African Union (AU) whose express objective is to stimulate Africa’s
development by bridging existing gaps in Infrastructure (Energy, Water and Sanitation,
Transport and ICT); Agriculture and Food Security; Human Resource Development, especially
Health/Education, Youth and Training, Social Affairs; Science, Technology and Innovation;
Trade, Industry/Market Access and Private Sector Development; Environment/Climate
Change and Tourism; Governance/Public Administration, Peace and Security; Capacity
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Development, and Gender Development. The implementation of these programmes is based
on the AU/NEPAD principles of African leadership and the ownership of the continent’s
development agenda and process, as well as a commitment to good political, economic and
corporate governance. African leaders have explicitly recognized that socio-economic trans‐
formation of the continent cannot be achieved without increased investments in science,
technology, and innovation. To that end, the leaders have initiated a number of concrete actions
geared towards promoting the continent’s scientific and technological development. The
actions include the creation of the African Ministerial Council on Science and Technology
(AMCOST) and its subsidiary bodies -- the NEPAD Office of Science and Technology, and the
AU Commission for Human Development, Science and Technology. These institutions have
collectively developed a comprehensive strategy and action plan -- Africa’s Science and
Technology Consolidated Plan of Action -- adopted at the second African Ministerial Confer‐
ence on Science and Technology in Dakar, Senegal, in September 2005. The main goals of
Africa’s Science and Technology Consolidated Plan of Action (CPA) are to strengthen Africa’s
capacities to develop, harness and apply science, technology, and innovation to achieve
millennium development goals (MDGs), as well as mobilizing the continent’s expertise and
institutions to contribute to the global pool of science and technological innovations. Key to
these goals is the promotion of transnational Research and Development (R&D) programmes
4.7.1. Technological trends and Innovation systems in public health delivery in Africa
There is need for a common and shared understanding of what can be done in order to tap
science, technology and innovation tools to address Africa’s current huge burden of disease.
First, African countries and institutions have to show the qualities of leadership necessary for
generating and utilizing technology and innovations in health in order to address diseases that
are peculiar to this continent. It is evident that many of these diseases are not being addressed
by the global scientific community for reasons which need no enumerating here. This can only
be Africa’s responsibility. Secondly, Africa needs to position itself strategically with regard to
shaping and driving a new research and innovation agenda necessary for disease treatment
and diagnosis. Today, the continent does not have access to relevant health innovation tools
that are widely available around the world. Worse still, Africa is not a key player in the public
health research and innovation enterprises. Inequality in science, technology and health
innovation capacity in Africa is evident in the extent of the disease burden in many countries.
Consequently, the current global funding arrangements for public health, including for global
pandemics like HIV/AIDS and neglected diseases, must go beyond merely treating the
symptoms through the provision of treatment but should also focus on building requisite
health research and development [53] infrastructure on the continent. Thirdly, new continental
initiatives must focus on shifting the apparent successes in health innovations to product
development and product delivery. It is evident that while promising innovations have been
developed in Africa and/or for Africa’s specific diseases, not many investments are taking place
in product development and product delivery. It is therefore important to address this
shortcoming in the context of the Africa health strategies for NEPAD and the AU.
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Finally, Africa must take advantage of the wide pool of scientific knowledge and technology
tools available globally. This means that, on the one hand, individual countries and continental
institutions must invest in technology prospecting in order to exploit existing and relevant
health technologies and products. On the other hand, Africa must invest in setting up or
transforming research institutions that are not only knowledge-based but also oriented
towards product development. There is an immediate need to strengthen African institutions,
especially universities and schools of medicine, by increasing funding and revising the
curricula. Thus the issue of how science, technology and innovation can alleviate Africa’s
burden of disease.
4.7.2. Ethics in European Union research
Public attitudes towards science and technology are overwhelmingly positive. The confidence
generated by messages such as 'scientifically tested' or 'scientifically proven' is testament to
society's support of scientific endeavour. It also highlights the social responsibility that
accompanies research. As science advances and evolves, and the relationship between science
and society gets better explanations, new challenges are created for the scientific community.
Nowadays, there are more scientists than ever before. On a regular basis, exciting research
opportunities spring into existence. Grant driven projects and non funded projects are larger,
more complex, and more expensive. The role that science plays in our lives continues to gain
more significance and recognition in importance, and society, in turn, has a stake in science.
Consequently, the relationship between science and society continues to change and intensify
in the pursuit of progress [54].
Excellence in science means addressing ethical concerns - to improve the quality of the science
itself, but also to highlight the importance of its outcomes to the wider community. The EU's
commitment to ethics in research is reflected in explicit requirements, and more specifically in
the evaluation of project proposals. Ethics may be context-dependent, but any research team's
approach to ethical matters is taken as an indication of the honesty and the clarity of its
proposal. While there are rarely clear-cut answers when it comes to ethics, some areas are
excluded from EU funding by definition. These are human cloning for reproductive purposes,
altering the genetic heritage of human beings, and creating human embryos only to conduct
research or obtain stem cells [54].
5. Conclusion
The population of low income economies are highly vulnerable in medical research. The
fundamental ethical principles need to have its place in the global public health research
sectors. With the increase research in finding new investigational products, developing new
disease diagnostics techniques puts the human population into a vulnerable position vis a vis
participation into clinical research trials. It is therefore imperative for the public health sector
to place more emphasis in the implementation of research that is ethical. By so doing the
fundamental principle of morality, autonomy and respect for others, beneficence, non-
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maleficence and justice shall be practicable and sustainable as within the universal declaration
of Helsinki. The public health sector in both developing and developed nations has a duty to
set up a working platform that may reduce the 10/90 gap that has remained static in the sub-
Saharan Africa. Medical research should be undertaken in the low income economies in order
to further the understanding and treatment of poverty related diseases, primarily for the
benefit of those in the developing world, not rather for the benefit of citizens of the developed
world. Ethics is therefore a non negotiable principle and policy in Public Health Clinical
Research practice. It is also evident with increasing clinical research that there shall be more
potential legal issues. This calls for more scrutiny in the institutions that be in regulating the
ethical framework in the conduct of human research. Those implicate in research should ensure
that they are fully versed with their legal rights and obligations associated with the research
they are engaged in, and also in tuned with the import and export regulations relevant to
biological material transfer, data sharing as the shortcoming of these regulation are potential
points for legal liability.
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